Brinckerhoff Discusses Recent Federal Circuit Decision on Biosimilar with Bloomberg Law
December 15, 2017
Bloomberg Law Patent, Trademark & Copyright Journal – Daily Edition
Partner Courtenay Brinckerhoff was quoted in a Bloomberg Law Patent, Trademark & Copyright Journal – Daily Edition article, “Biosimilars Statute Trumps State Law, Appeals Court Rules,” about a recent U.S. Court of Appeals for the Federal Circuit ruling on the Biologics Price Competition and Innovation Act.
The court, in a December 14, 2017, ruling, held that the statute, which provides a relatively quick path for biosimilar makers to get new drug products to market, supersedes state law claims. The ruling was the second big win for biosimilar applicants this year. Earlier the U.S. Supreme Court allowed a biosimilar applicant to skip a notice period to a biologic owner before marketing its biosimilar product.
“The decision favors biosimilar applicants in that it forecloses a state law remedy for failing to comply with the BPCIA information exchange procedures, and thereby confirms that doing so is completely optional,” Brinckerhoff said. “Since the field of biosimilar litigation is relatively new, the decision does not upset any long-settled practices, although existing cases may include similar state law claims that may not survive this decision.”
The court, in a December 14, 2017, ruling, held that the statute, which provides a relatively quick path for biosimilar makers to get new drug products to market, supersedes state law claims. The ruling was the second big win for biosimilar applicants this year. Earlier the U.S. Supreme Court allowed a biosimilar applicant to skip a notice period to a biologic owner before marketing its biosimilar product.
“The decision favors biosimilar applicants in that it forecloses a state law remedy for failing to comply with the BPCIA information exchange procedures, and thereby confirms that doing so is completely optional,” Brinckerhoff said. “Since the field of biosimilar litigation is relatively new, the decision does not upset any long-settled practices, although existing cases may include similar state law claims that may not survive this decision.”
People
Related News
June 10, 2025
In the News
James McFall Joins Iconic Athletes and Leaders in Launch of Stanford Football Alumni United
Foley & Lardner LLP is proud to announce that partner James Carlos McFall is a founding member of Stanford Football Alumni United (SFAU), a newly formed coalition of former players and leaders committed to supporting Stanford Football’s continued growth and national competitiveness.
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."
June 6, 2025
In the News
Louis Lehot Comments on Crypto Company IPO – 'Definitely a home run'
Foley & Lardner LLP partner Louis Lehot commented on the initial public offering of stablecoin issuer Circle in the Law360 article, "Circle's Smash IPO Could Pave Way For More Crypto Listings."